1) World Health Organization:Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity. Vitamin and Mineral Nutrition Information System. World Health Organization, 2011(WHO/NMH/NHD/MNM/11.1). http://www.who.int/vmnis/indicators/haemoglobin.pdf(2022年2月閲覧)
2) 白倉卓夫, 他:老年者末梢血像と赤血球産生能の変化. 日老医誌 1978;15:151-157.
3) 樋口敬和:血算(全血球計算)の読み方. In:矢崎義雄 監修, 徳田安春, 他 編:新臨床内科学, 第10版. 医学書院, 2020:968-973.
4) Means RT, et al.:Anemia:general considerations. In:Greer JP, et al., eds, Wintrobe's Clinical Hematology, 14th ed. Wolters Kluwer, 2019;588-614.
5) 樋口敬和:貧血の鑑別のアプローチは? In:神田善伸 編:むかしの頭で診ていませんか? 血液診療をスッキリまとめました. 南江堂, 2017:1-7.
6) Nardone DA, et al.:Usefulness of physical examination in detecting the presence or absence of anemia. Arch Intern Med 1990;150:201-204.
7) Kalantri A, et al.:Accuracy and reliability of pallor for detecting anaemia:A hospital-based diagnostic accuracy study. PLoS One 2010;5:e8545.
8) Strobach RS, et al.:The value of the physical examination in the diagnosis of anemia. correlation of the physical findings and the hemoglobin concentration. Arch Intern Med 1988;148:831-832.
9) Sheth TN, et al.:The relation of conjunctival pallor to the presence of anemia. J Gen Intern Med 1997;12:102-106.
10) Nardone DA, et al.:Usefulness of physical examination in detecting the presence or absence of anemia. Arch Intern Med 1990;150:201-204.
11) McGee S 著, 徳田安春 総監訳, 志水太郎, 他 監訳:マクギーのフィジカル診断学, 原著第4版. 診断と治療社, 2019:65(McGee S:Evidence-Based Physical Diagnosis, 4th ed. Elsevier, 2017).
12) World Health Organization:Serum ferritin concentrations for the assessment of iron status in individuals and populations:technical brief. World Health Organization, 2020. https://apps.who.int/iris/handle/10665/337666(2022年2月閲覧)
13) Camaschella C:Iron-deficiency anemia. N Engl J Med 2015;372:1832-1843.
14) Lopez A, et al.:Iron deficiency anaemia. Lancet 2016;387:907-916.
15) Pasricha S, et al.:Iron deficiency. Lancet 2021;397:233-248.
16) Krayenbuehl P, et al.:Intravenous iron for the treatment of fatigue in nonanemic, premenopausal women with low serum ferritin concentration. Blood 2011;118:3222-3227.
17) Houston BL, et al.:Efficacy of iron supplementation on fatigue and physical capacity in non-anaemic iron-deficient adults:A systematic review of randomised controlled trials. BMJ Open 2018;8:e019240.
18) Munoz M, et al.:Current misconceptions in diagnosis and management of iron deficiency. Blood Transfus 2017;15:422-437.
19) Elstrott B, et al.:The role of iron repletion in adult iron deficiency anemia and other diseases. Eur J Haematol 2020;104:153-161.
20) Girelli D, et al.:Modern iron replacement therapy:Clinical and pathophysiological insights. Int J Hematol 2018;107:16-30.
21) 山城安啓:サラセミアの基礎知識と臨床検査. Med Technol 2015;43:1110-1117.
22) Taher AT, et al.:Thalassaemia. Lancet 2018;391:155-167.
23) Ganz T:Anemia of inflammation. N Engl J Med 2019;381:1148-1157.
24) Fraenkel PG:Anemia of inflammation:A review. Med Clin North Am 2017;101:285-296.
25) Poggiali E, et al.:Anemia of chronic disease:A unique defect of iron recycling for many different chronic diseases. Eur J Intern Med 2014;25:12-17.
26) Gangat N, et al.:Anemia of chronic disease. Semin Hematol 2013;50:232-238.
27) 赤芽球癆診療の診断基準と診療の参照ガイド改訂版作成のためのワーキンググループ:赤芽球癆診療の参照ガイド令和1年改訂版(第6版). 厚生労働科学研究費補助金 難治性疾患等政策研究事業 特発性造血障害に関する調査研究班(研究代表者 三谷絹子), 2020. http://zoketsushogaihan.umin.jp/file/2020/03.pdf(2022年2月閲覧)
28) 廣川誠:赤芽球癆診療の進歩と今後の展望. 臨血 2016;57:110-116.
29) Means RT:Pure red cell aplasia. Blood 2016;128:2504-2509.
30) Hirokawa M, et al.:Long-term response and outcome following immunosuppressive therapy in thymoma-associated pure red cell aplasia:A nationwide cohort study in japan by the PRCA collaborative study group. Haematologica 2008;93:27-33.
31) 発作性夜間ヘモグロビン尿症(PNH)の診断基準と診療の参照ガイド改訂版作成のためのワーキンググループ:発作性夜間ヘモグロビン尿症診療の参照ガイド令和1年改訂版. 厚生労働科学研究費補助金 難治性疾患等政策研究事業 特発性造血障害に関する調査研究班(研究代表者 三谷絹子), 2020. http://zoketsushogaihan.umin.jp/file/2020/06v2.pdf(2022年2月閲覧)
32) 後藤明彦:発作性夜間ヘモグロビン尿症診療の参照ガイド-最近のアップデートと診療のポイント. 臨血 2020;61:1080-1088.
33) Brodsky RA:Paroxysmal nocturnal hemoglobinuria. Blood 2014;124:2804-2811.
34) Devalet B, et al.:Pathophysiology, diagnosis, and treatment of paroxysmal nocturnal hemoglobinuria:A review. Eur J Haematol 2015;95:190-198.
35) Capecchi M, et al.:Thrombotic complications in patients with immune-mediated hemolysis. J Clin Med 2021;10:1764.
36) Hillmen P, et al.:Long-term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuria. Br J Haematol 2013;162:62-73.
37) Lee JW, et al.:Ravulizumab(ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors:The 301 study. Blood 2019;133:530-539.
38) Kulasekararaj AG, et al.:Ravulizumab(ALXN1210) vs eculizumab in C5-inhibitorexperienced adult patients with PNH:The 302 study. Blood 2019;133:540-549.
39) Takahashi N, et al.:Causes of macrocytic anemia among 628 patients:mean corpuscular volumes of 114 and 130 fL as critical markers for categorization. Int J Hematol 2016;104:344-357.
40) Wickramasinghe SN:Diagnosis of megaloblastic anaemias. Blood Rev 2006;20:299-318.
41) Snow CF:Laboratory diagnosis of vitamin B12 and folate deficiency:A guide for the primary care physician. Arch Intern Med 1999;159:1289-1298.
42) Stabler SP:Clinical practice. vitamin B12 deficiency. N Engl J Med 2013;368:149-160.
43) 樋口敬和:鉄剤・葉酸・ビタミンB12. In:中尾眞二, 他 編:血液疾患最新の治療2020-2022. 南江堂, 2019:61-64.
44) Carmel R:How I treat cobalamin(vitamin B12) deficiency. Blood 2008;112:2214-2221.
45) Shipton MJ, et al.:Vitamin B12 deficiency-A 21st century perspective. Clin Med (Lond) 2015;15:145-150.
46) Andres E, et al.:Oral cobalamin(vitamin B(12)) treatment. an update. Int J Lab Hematol 2009;31:1-8.
47) Mahmoud MY, et al.:Unexplained macrocytosis in elderly patients. Age Ageing 1996;25:310-312.
48) 自己免疫性溶血性貧血の診断基準と診療の参照ガイド改訂版作成のためのワーキンググループ:自己免疫性溶血性貧血診療の参照ガイド 令和1年改訂版. 厚生労働科学研究費補助金 難治性疾患等政策研究事業 特発性造血障害に関する調査研究班(研究代表者 三谷絹子), 2020. http://zoketsushogaihan.umin.jp/file/2020/09.pdf(2022年2月閲覧)
49) Jager U, et al.:Diagnosis and treatment of autoimmune hemolytic anemia in adults:Recommendations from the first international consensus meeting. Blood Rev 2020;41:100648.
50) Hill QA, et al.:The diagnosis and management of primary autoimmune haemolytic anaemia. Br J Haematol 2017;176:395-411.
51) Brodsky RA:Warm autoimmune hemolytic anemia. N Engl J Med 2019;381:647-654.
52) Berentsen S, et al.:Autoimmune hemolytic anemias. N Engl J Med 2021;385:1407-1419.
53) Spivak JL:Masked megaloblastic anemia. Arch Intern Med 1982;142:2111-2114.
54) Hash RB, et al.:Anemia secondary to combined deficiencies od iron and cobalamin. Arch Fam Med 1996;5:585-588.